Brian Piekos - Net Worth and Insider Trading

Brian Piekos Net Worth

The estimated net worth of Brian Piekos is at least $584,847 dollars as of 2026-08-13. Brian Piekos is the CFO of KalVista Pharmaceuticals Inc and owns about 21,661 shares of KalVista Pharmaceuticals Inc (KALV) stock worth over $584,847. Details can be seen in Brian Piekos's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Brian Piekos has not made any transactions after 2026-05-22 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Brian Piekos

Are these stocks worth buying? — GuruFocus analysis for each holding

- GF

KALV KalVista Pharmaceuticals Inc

100% of holdings · $585K

Brian Piekos Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Brian Piekos owns 4 companies in total, including AMAG Pharmaceuticals Inc (AMAG) , Disc Medicine Inc (IRON) , and Elicio Therapeutics Inc (ELTX) among others .

Click here to see the complete history of Brian Piekos’s form 4 insider trades.

Insider Ownership Summary of Brian Piekos

Ticker	Company	Transaction Date	Type of Owner
AMAG	AMAG Pharmaceuticals Inc	2020-06-09	Interim CFO
IRON	Disc Medicine Inc	2021-05-14	Chief Financial Officer
ELTX	Elicio Therapeutics Inc	2023-06-01	Chief Financial Officer
		2026-05-22	Chief Financial Officer

Brian Piekos Latest Holdings Summary

Brian Piekos currently owns a total of 1 stock. Brian Piekos owns 21,661 shares of KalVista Pharmaceuticals Inc (KALV) as of May 22, 2026, with a value of $584,847.

Latest Holdings of Brian Piekos

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
KALV	KalVista Pharmaceuticals Inc	2026-05-22	21,661	27.00	584,847

Holding Weightings of Brian Piekos

Brian Piekos Form 4 Trading Tracker

According to the SEC Form 4 filings, Brian Piekos has made a total of 4 transactions in KalVista Pharmaceuticals Inc (KALV) over the past 5 years, including 0 buys and 4 sells. The most-recent trade in KalVista Pharmaceuticals Inc is the sale of 1,489 shares on May 22, 2026, which brought Brian Piekos around $39,875.

Insider Trading History of Brian Piekos

* The information on this page (including Insider Trading Shares, Share Changes, Cost, etc.) is sourced exclusively from Form 4 filings and does not incorporate any data from 13F or 13D/G filings. As a result, it may differ from the values shown on the Guru page.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Brian Piekos Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Get the full picture on these stocks

See GF Score, valuation, financials, and warning signs for every stock Brian Piekos owns.

- KALV

View KALV Analysis

Brian Piekos Ownership Network

Ownership Network List of Brian Piekos

No Data

Ownership Network Relation of Brian Piekos

Brian Piekos Owned Company Details

What does AMAG Pharmaceuticals Inc do?

Who are the key executives at AMAG Pharmaceuticals Inc?

Brian Piekos is the Interim CFO of AMAG Pharmaceuticals Inc. Other key executives at AMAG Pharmaceuticals Inc include 10 percent owner Camber Capital Management Llc , Chief Operating Officer Anthony Casciano , and director & 10 percent owner David Edward Johnson .

AMAG Pharmaceuticals Inc (AMAG) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of AMAG Pharmaceuticals Inc (AMAG) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of AMAG Pharmaceuticals Inc (AMAG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

AMAG Pharmaceuticals Inc (AMAG)'s detailed insider trading history can be found in Insider Trading Tracker table.

AMAG Pharmaceuticals Inc Insider Transactions

No Available Data

What does Disc Medicine Inc do?

Who are the key executives at Disc Medicine Inc?

Brian Piekos is the Chief Financial Officer of Disc Medicine Inc. Other key executives at Disc Medicine Inc include General Counsel Rahul Khara , director & Chief Executive Officer John D Quisel , and Chief Business Officer Jonathan Yen-wen Yu .

Disc Medicine Inc (IRON) Insider Trades Summary

Over the past 18 months, Brian Piekos made no insider transaction in Disc Medicine Inc (IRON). Other recent insider transactions involving Disc Medicine Inc (IRON) include a net sale of 455,344 shares made by Kevin Bitterman , a net sale of 42,869 shares made by William Jacob Savage , and a net sale of 165,838 shares made by John D Quisel .

In summary, during the past 3 months, insiders sold 110,712 shares of Disc Medicine Inc (IRON) in total and bought 0 shares, with a net sale of 110,712 shares. During the past 18 months, 2,275,268 shares of Disc Medicine Inc (IRON) were sold and 0 shares were bought by its insiders, resulting in a net sale of 2,275,268 shares.

Disc Medicine Inc (IRON)'s detailed insider trading history can be found in Insider Trading Tracker table.

Disc Medicine Inc Insider Transactions

No Available Data

What does Elicio Therapeutics Inc do?

Who are the key executives at Elicio Therapeutics Inc?

Brian Piekos is the Chief Financial Officer of Elicio Therapeutics Inc. Other key executives at Elicio Therapeutics Inc include See Remarks Preetam Shah , 10 percent owner Gkcc, Llc , and director & 10 percent owner Yekaterina Chudnovsky .

Elicio Therapeutics Inc (ELTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Elicio Therapeutics Inc (ELTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Elicio Therapeutics Inc (ELTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Elicio Therapeutics Inc (ELTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Elicio Therapeutics Inc Insider Transactions

No Available Data

What does KalVista Pharmaceuticals Inc do?

Who are the key executives at KalVista Pharmaceuticals Inc?

Brian Piekos is the Chief Financial Officer of KalVista Pharmaceuticals Inc. Other key executives at KalVista Pharmaceuticals Inc include Chief Development Officer Christopher Yea , Chief Medical Officer Paul K. Audhya , and Chief Commercial Officer Nicole Sweeny .

KalVista Pharmaceuticals Inc (KALV) Insider Trades Summary

Over the past 18 months, Brian Piekos made 4 insider transaction in KalVista Pharmaceuticals Inc (KALV) with a net sale of 9,589. Other recent insider transactions involving KalVista Pharmaceuticals Inc (KALV) include a net sale of 159,407 shares made by Benjamin L Palleiko , a net sale of 100,279 shares made by Christopher Yea , and a net sale of 44,877 shares made by Paul K. Audhya .

In summary, during the past 3 months, insiders sold 62,082 shares of KalVista Pharmaceuticals Inc (KALV) in total and bought 0 shares, with a net sale of 62,082 shares. During the past 18 months, 545,127 shares of KalVista Pharmaceuticals Inc (KALV) were sold and 25,000 shares were bought by its insiders, resulting in a net sale of 520,127 shares.

KalVista Pharmaceuticals Inc (KALV)'s detailed insider trading history can be found in Insider Trading Tracker table.

KalVista Pharmaceuticals Inc Insider Transactions

No Available Data

Brian Piekos Mailing Address

Above is the net worth, insider trading, and ownership report for Brian Piekos. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Brian Piekos's mailing address is: Cambridge Ma 02142.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.